Supernus Pharmaceuticals (SUPN) Retained Earnings (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Retained Earnings of $574.1 million for Q2 2026, up 1.23% year-over-year from $567.1 million in Q2 2025, and up 2.26% on a QoQ basis from $561.4 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Retained Earnings (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Retained Earnings for 16 years, with the latest figure at $574.1 million in Q2 2026.
- Retained Earnings for Q2 2026 came in at $574.1 million, up 1.23% year-over-year; the trailing twelve-month figure through Jun 2026 was $574.1 million (up 1.23% YoY), and the FY2025 annual result was $543.8 million, down 2.26% from the prior year.
- Retained Earnings advanced to $574.1 million in Q2 2026, from $561.4 million in the prior quarter.
- Over five years, Retained Earnings peaked at $574.1 million in Q2 2026 and troughed at $446.2 million in Q1 2022.
- A 5-year average of $511.0 million and a median of $500.4 million in 2023 frame the typical range for Retained Earnings.
- The largest YoY upside for Retained Earnings was 15.31% in 2024 against a maximum downside of 3.11% in 2024.
- A 5-year view of Retained Earnings shows it stood at $481.2 million in 2022, then rose by 0.27% to $482.6 million in 2023, then grew by 15.31% to $556.4 million in 2024, then retreated by 2.26% to $543.8 million in 2025, then grew by 5.57% to $574.1 million in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were $574.1 million in Q2 2026, $561.4 million in Q1 2026, and $543.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 37.15 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 28.26 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 14.65 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 4.18 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 9.16 Bn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 18.56 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 724.00 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 8.88 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 3.75 Bn |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.37 Bn | 185.39 Mn | 574.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 574.09 Mn |
| Mar 31, 2026 | -255,000.00 |
| Dec 31, 2025 | 517.88 Mn |
| Sep 30, 2025 | 527.70 Mn |
| Jun 30, 2025 | 496.95 Mn |
| Mar 31, 2025 | 544.60 Mn |
| Dec 31, 2024 | 479.44 Mn |
| Sep 30, 2024 | 541.10 Mn |
| Jun 30, 2024 | 502.60 Mn |
| Mar 31, 2024 | 446.96 Mn |
| Dec 31, 2023 | 439.49 Mn |
| Sep 30, 2023 | 431.96 Mn |
| Jun 30, 2023 | -1.78 Mn |
| Mar 31, 2023 | 416.23 Mn |
| Dec 31, 2022 | 481.25 Mn |
| Sep 30, 2022 | 401.03 Mn |
| Jun 30, 2022 | 454.02 Mn |
| Mar 31, 2022 | 446.15 Mn |
| Dec 31, 2021 | 434.34 Mn |
| Sep 30, 2021 | 377.48 Mn |